Mechanisms of corneal allograft rejection.
More effective therapies are required to improve clinical corneal allograft outcomes. The strategies that have led to improvements in vascularized organ graft survival are not always applicable to the cornea. New treatments that modulate the afferent arm of the immune response to a corneal allograft are more likely to prove effective than are treatments that target the effector arm of the immune response. We briefly discuss two such options: the use of engineered antibody fragments to block antigen presentation, and the use of gene therapy approaches to abrogate antigen presenting-cell function.
Coster
Douglas J
DJ
Department of Ophthalmology, Flinders University, Adelaide, Australia. doug.coster@flinders.edu.au
Jessup
Claire F
CF
Biotech
B
B
Williams
Keryn A
KA